Reply to Periclou et al.: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”

A Related Article is available

The Original Article is available

This is a preview of subscription content, log in to check access.


  1. 1.

    Periclou A, Riccobene T, Kapás M, et al. Comment on: “Clinical pharmacokinetics of atypical antipsychotics: an update”. Clin Pharmacokinet. 2019.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493–528.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195–235.

    Article  Google Scholar 

  4. 4.

    Nakamura T, Kubota T, Iwakaji A, et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther. 2016;10:327–38.

    CAS  Article  Google Scholar 

  5. 5.

    Carrothers T, Willavize S, Jaworowicz DJ, et al. Relationship of cariprazine plasma concentration to efficacy and safety in patients with schizophrenia or bipolar mania [poster]. American Psychiatric Association (APA) Annual Meeting; 14–18 May 2016; Atlanta. Accessed 13 June 2019.

Download references

Author information



Corresponding author

Correspondence to Massimo Carlo Mauri.

Ethics declarations


No external funding was used in the preparation of this reply.

Conflict of interest

Massimo Carlo Mauri has no conflicts of interest that are directly relevant to the contents of this reply.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mauri, M.C. Reply to Periclou et al.: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”. Clin Pharmacokinet 58, 1217–1218 (2019).

Download citation